Neff Robert T, Senter Leigha, Salani Ritu
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Department of Internal Medicine, Division of Human Genetics, The Ohio State University Wexner Medical Center Columbus, OH, USA.
Ther Adv Med Oncol. 2017 Aug;9(8):519-531. doi: 10.1177/1758834017714993. Epub 2017 Jun 19.
Ovarian cancer is a heterogeneous disease that encompasses a number of different cellular subtypes, the most common of which is high-grade serous ovarian cancer (HGSOC). Still today, ovarian cancer is primarily treated with chemotherapy and surgery. Recent advances in the hereditary understanding of this disease have shown a significant role for the gene. While only a minority of patients with HGSOC will have a germline mutation, many others may have tumor genetic aberrations within BRCA or other homologous recombination proteins. Genetic screening for these mutations has allowed improved preventative measures and therapeutic development. This review focuses on the understanding of mutations and their relationship with ovarian cancer development, as well as future therapeutic targets.
卵巢癌是一种异质性疾病，包含多种不同的细胞亚型，其中最常见的是高级别浆液性卵巢癌（HGSOC）。时至今日，卵巢癌主要通过化疗和手术进行治疗。对该疾病遗传方面的最新研究进展表明，[基因名称]基因发挥着重要作用。虽然只有少数HGSOC患者会发生胚系[基因名称]突变，但其他许多患者可能在BRCA或其他同源重组蛋白中存在肿瘤基因畸变。对这些[基因名称]突变进行基因筛查有助于改进预防措施和推动治疗方法的研发。本综述着重阐述对[基因名称]突变的认识及其与卵巢癌发生发展的关系，以及未来的治疗靶点。
